Compare SLGN & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGN | IMVT |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 5.0B |
| IPO Year | 1994 | 2019 |
| Metric | SLGN | IMVT |
|---|---|---|
| Price | $41.28 | $24.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $52.78 | $30.78 |
| AVG Volume (30 Days) | 752.3K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $4,489,927,000.00 | N/A |
| Revenue This Year | $4.83 | N/A |
| Revenue Next Year | $2.13 | N/A |
| P/E Ratio | $15.46 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $36.15 | $13.36 |
| 52 Week High | $57.04 | $29.25 |
| Indicator | SLGN | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 47.09 |
| Support Level | $37.10 | $22.25 |
| Resistance Level | $41.79 | $25.32 |
| Average True Range (ATR) | 0.94 | 1.25 |
| MACD | 0.52 | 0.13 |
| Stochastic Oscillator | 81.49 | 51.69 |
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.